Comments

Coherus BioSciences Stock Price, Quotes and Forecasts

Q: What sector and industry does Coherus BioSciences (CHRS) operate in?

Coherus BioSciences is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

CHRSNASDAQ

Logo brought to you by Benzinga Data

Perks Buy Compare Brokers

$1.04

0.043.48%

Pre-Market: 7:59 PM EDT

Q4 2024 Earnings in 6 days from now on Mon Mar 10th, after the market close

Conference call scheduled in 6 days at 17:00 PM Click to view the webcast

Coherus BioSciences (CHRS) Forecast

News Earnings Coherus BioSciences (CHRS) Options Guidance Dividends Analyst Ratings Insider Trades Government Trades Short Interest

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Coherus BioSciences Stock Price, Quotes and Forecasts | NASDAQ:CHRS | Benzinga

Explore Coherus BioSciences stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for CHRS.

Open	-
Close	-
Volume / Avg.	0 / 4.38M
Day Range	- - -
52 Wk Range	0.66 - 2.64
Market Cap	$120.53M
P/E Ratio	-
Dividend Yield	-
Exchange	NASDAQ
RSI	34
Short Interest	32.02%
Days to Cover	26.61

Recent News

Why Is Coherus BioSciences Stock Trading Higher On Tuesday?

Coherus sells Udenyca franchise for up to $558.4 million, shifts focus to immuno-oncology R&D, and plans clinical trials in hepatocellular carcinoma and NSCLC.

Vandana Singh

Why CommScope Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Monday's Mid-Day Session

Shares of CommScope Holding Company, Inc. (NASDAQ: COMM) fell sharply during Monday’s session. B of A Securities analyst Tal Liani downgraded CommScope from Neutral to Underperform and lowered the price target from $2.1 to $2. CommScope shares dipped 6.9% to $2.2150 on Monday.

Avi Kapoor

Why Is Cancer Immunotherapy Focused-Coherus BioSciences Stock Trading Higher Today?

Coherus BioSciences agreed to sell its ophthalmology franchise for $170M to Sandoz. This aligns with CHRS' focus on oncology and will help reduce debt and overhead costs.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Analyst Trends and Forecast

Sep 24

Nov 24

Dec 24

Jan

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

3.9

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Open	-
Close	-
Volume / Avg.	0 / 4.38M
Day Range	- - -
52 Wk Range	0.66 - 2.64
Market Cap	$120.53M
P/E Ratio	-
Dividend Yield	-
Exchange	NASDAQ
RSI	34
Short Interest	32.02%
Days to Cover	26.61

About Coherus Biosciences Inc

Sector

Health Care

Industry

Biotechnology

Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology ...

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

How do I buy Coherus BioSciences (CHRS) stock?

You can purchase shares of Coherus BioSciences (NASDAQ:CHRS) through any online brokerage.

View our list of the best stock brokerages

Who are Coherus BioSciences (CHRS) competitors?

Other companies in Coherus BioSciences’s space includes: Fate Therapeutics (NASDAQ:FATE), Kyverna Therapeutics (NASDAQ:KYTX), Genelux (NASDAQ:GNLX), TScan Therapeutics (NASDAQ:TCRX) and Lineage Cell Therapeutics (AMEX:LCTX).

What is the forecast, or price target, for Coherus BioSciences (CHRS) stock?

Coherus BioSciences has a consensus price target of $9.06.

What is the current price for Coherus BioSciences (CHRS)?

The stock price for Coherus BioSciences (NASDAQ: CHRS) is $1.04 last updated March 3, 2025 at 7:59 PM EST.

Does Coherus BioSciences (CHRS) pay a dividend?

There are no upcoming dividends for Coherus BioSciences.

When is Coherus BioSciences (NASDAQ:CHRS) reporting earnings?

Coherus BioSciences’s Q1 earnings are confirmed for Thursday, May 8, 2025.

Is Coherus BioSciences (CHRS) going to split?

There is no upcoming split for Coherus BioSciences.

What sector and industry does Coherus BioSciences (CHRS) operate in?

Coherus BioSciences is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.